

PATENT  
Docket No. 204372000320

## CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231.

8-27-97  
DateAlexandra H. Parsons  
Alexandra H. Parsons

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Lynn E. Spitler et al.

Serial No.: 08/288,057

Filing Date: 10 August 1994

For: PROSTATIC CANCER VACCINE

Examiner: P. Gambel

Group Art Unit: 1816

DECLARATION OF GARY R. MATYAS, PH.D.  
PURSUANT TO 37 C.F.R § 1.132Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

1, Gary R. Matyas, declare as follows:

1. I am engaged in medical research at the Walter Reed Army Institute of Research (WAIR) and have been active in studying cellular immune responses for 2 years. A copy of my *curriculum vitae* is attached hereto as Exhibit A.

2. Under my supervision, studies were performed using Balb/C mice. In order to generate cytotoxic T lymphocytes (CTL) in response to recombinant human prostate specific antigen (rhPSA) we immunized two groups of six mice per group with OncoVax<sup>PTM</sup> alone or with OncoVax<sup>PTM</sup> mixed with aluminum hydroxide (alum, Alhydrogel, 200 µg Al<sup>+++</sup>).

dc-85046

OncoVax<sup>PTM</sup> is a liposomal formulation of rhPSA with lipid A, and the PSA dose in this protocol was 5 µg rhPSA and 20 µg lipid A. The mice were immunized at week 0 and week 4 at these dosages and euthanized at 8 weeks. The spleens were removed and spleen cells harvested, pooled and incubated for 5 days either with medium alone or in medium containing 2 µg/ml rhPSA.

3. Target cells were P815 mouse mastocytoma cells infected either with wild-type vaccinia virus or with vaccinia virus transfected with the PSA gene and the *E. coli lacZ* gene (PSAVac, Therion Biologics Corp.) at a multiplicity of infection of 10. Alternatively, the P815 cells were incubated with 10 µg/ml of the peptide CYASGWGSI which represents a potential CTL epitope at positions 153-161 of PSA.

4. After incubation for 16 hours with vaccinia viruses or peptide, the target cells were labeled with Cr<sup>51</sup> (0.1 µCi/10<sup>6</sup> cells) for 1 hour).

5. The effector cells harvested from the mouse spleens were plated in 96-well u-bottom plates and the Cr<sup>51</sup> labeled target 815 cells were added at various effector:target ratios. The plates were centrifuged at 50xg for 5 minutes and then incubated at 37°C for 5 hours. The radioactivity present in the supernatant (indicative of cytotoxic activity of the effector cells) was harvested using Skatron wicks and quantified using a gamma counter.


6. The attached Exhibit B shows the results. As shown, spleen cells from mice injected with either OncoVax<sup>PTM</sup> or OncoVax<sup>PTM</sup> with alum were able to lyse target cells that had been transfected with the vaccinia virus (Panels A and B). OncoVax<sup>PTM</sup> injected mice in the absence of alum (panel E) were effective in lysing the targets labeled with peptide, although when alum was included in the formulation, the resulting spleen cells were less able to do so (panel F). P815 target cells unlabeled with either peptide or vaccinia-produced PSA were not lysed (panels C, D, G, and H).

7. These results demonstrate that immunization of mice with OncoVax<sup>PTM</sup> induces lymphocytes which kill tumor cells presenting PSA antigens, indicating an antitumor response.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are

punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Executed at Washington, D.C. on 26 August 1997, by

  
Gary R. Matyas

August, 1997

## CURRICULUM VITAE

Gary R. Matyas

**Office:**

Department of Membrane Biochemistry  
Walter Reed Army Institute of Research  
Washington DC 20307-5100  
(202) 782-0875

**Home:**

18415 Snowberry Way  
Olney, MD 20832  
(301) 570-0610

**CAREER AIMS:** Research/management of membrane biochemistry laboratory with emphasis on liposome based vaccines, lipid mediators, and lipid changes during cell growth.

**PERSONAL:** Born April 30, 1956 in Berwick, PA; married, one child

**EDUCATION:**

**Graduate** Purdue University, West Lafayette, IN 47907  
Ph.D. degree; May 1985; Department of Biological Sciences  
Major Professor: D. James Morré

**Undergraduate** Pennsylvania State University, University Park, PA 16802  
B.S. degree; May 1978; Major - Biophysics

**EXPERIENCE:**

**Research** **Research Chemist**  
Department of Membrane Biochemistry  
Division of Biochemistry  
Walter Reed Army Institute of Research  
Washington DC 20307  
September 1988 to present  
Supervisor: Dr. Carl R. Alving

**Projects:**

- I. Development of active site monoclonal antibodies to cobra venom phospholipase A<sub>2</sub>; Inhibitors of enzyme activity

**Gary R. Matyas**

**Curriculum Vitae (continued)**

**WRAIR Projects (cont.):**

- II Mechanism of concanavalin A induced killing of mice and cultured cells
- II Incorporation of bioactive lipids into liposomes: Effect on immune response to liposome encapsulated antigens
- IV Development of monoclonal antibodies to sphingosine and sphingolipids
- V Development of a liposomal vaccine against ricin intoxication
- VI In collaboration with Jenner Technologies, development, manufacture and testing of liposomal based cancer vaccine in human clinical trials
- VII Development of a liposomal vaccine protects against Ebola virus infection through the induction of cytotoxic lymphocytes.

**Additional Duties:**

- I Division of Biochemistry Safety Officer, Division representative to WRAIR safety council; Responsibilities include: Monthly safety inspections of division laboratories; Conducting training on safety concerns; Maintaining division training records.
- II. Terminal Security Officer for the Department of Membrane Biochemistry; Duties include: Maintaining security on computer equipment in the department; Procuring of IBM compatible equipment and software.

**Staff Fellow**

**Membrane Biochemistry Section**

**Laboratory of Molecular and Cellular Neurobiology/Developmental and Metabolic Neurology Branch**

**National Institute of Neurological, Communicative Disorders and Stroke**

**National Institutes of Health**

**Bethesda, MD 20892**

**April 1985 to September 1988**

**Supervisor: Dr. Peter Fishman**

**Projects:**

- I. Glycolipid alterations induced by transfection of NIH/3T3 cells with oncogenes.
- II. Alterations of glycolipids during cell growth.

**Gary R. Matyas**

**Curriculum Vitae (continued)**

**NIH projects (cont.)**

- II Production of glycolipid crosslinking reagents for the study of the involvement of glycolipids in cell adhesion and cell growth.
- IV. The role of *ras* oncogenes in phospholipase C mediated phosphoinositide hydrolysis.

**Graduate Assistant**

Department of Biological Sciences

Purdue University

West Lafayette, IN 47907

August 1978 to April 1985

Supervisor: Dr. D. James Morré

**Projects:**

- I. Interaction of fibronectin with gangliosides.
- II Subcellular distribution and biosynthesis of gangliosides in rat liver.
- III. Loss of fibronectin and complex gangliosides in metastatic rat tumors.
- IV. Elevated levels of serum gangliosides as a means of early detection of cancer.
- V. Cytochemical localization of glycosyltransferases.

**Research Assistant**

Department of Biochemistry and Biophysics

Pennsylvania State University

University Park, PA 16802

September 1977 to May 1988

Supervisor: Dr. Wallace Snipes

**Project:**

- I. Inactivation of lipid-containing viruses through physical perturbation of membranes.

**Gary R. Matyas**

**Curriculum Vitae (continued)**

**Teaching**

**Instructor**

Introductory Microbiology Laboratory  
Department of Biological Sciences  
Purdue University  
West Lafayette, IN 47907  
January 1981 to May 1981  
Supervisor: Dr. David Filmer

**Teaching Assistant**

Introductory Microbiology Laboratory  
Department of Biological Sciences  
Purdue University  
West Lafayette, IN 47907  
August 1979 to May 1980, August 1978 to May 1979  
Supervisors: Dr. Allen Konopka and Dr. David Filmer

**AWARDS:**

Special Purdue Fellowship  
Purdue University  
West Lafayette, IN 47907  
August 1980 to December 1980; \$2,000

Marion County Cancer Society (Little Red Door) Fellowship  
1801 North Meridian Street, Indianapolis, IN 46202  
"A New Serodiagnostic Parameter for Early Detection of Cancer  
That May Distinguish Localized and Disseminated Disease"  
January 1982 to December 1982; \$12,498

Milheim Foundation for Cancer Research  
Colorado National Bank  
Seventeenth Street at Champa  
Denver, CO 80202  
"The Biochemical Basis for Metastasis"  
July 1982 to June 1983; \$11,421

Gary R. Matyas

**Curriculum Vitae (continued)**

David Ross Fellowship  
Purdue University  
West Lafayette, IN 47907  
"Protein Kinase Modulations as Early Events of Tumorigenic  
Progression"  
August 1983 to July 1985; \$13,200

**MEMBERSHIPS:**

American Association for the Advancement of Science  
1978 to present

American Society for Biochemistry and Molecular Biology  
1987 to present

American Society of Microbiology  
1996 to present



## BIBLIOGRAPHY

Gary R. Matyas

### PUBLICATIONS:

1. Matyas, G. R., Werderitsh, D. A., Morre, D. M. and Morre, D. J.: Comparison of Metastatic and Non-metastatic Transplantable Tumors from the Jaw Region of the Rat. Proceedings of the Indiana Academy of Science (1981) 91, 161-173.
2. Matyas, G. R. and Morre, D. J.: Coupling of Uridine-5'-Diphosphate (UDP) Formation and Nicotinamide Adenine Dinucleotide (NADH) Reduction for Cytochemical Localization of Glycosyltransferases. Journal of Histochemistry and Cytochemistry (1983) 31, 1175-1182.
3. Matyas, G. R. and Morre, D. J.: Isolation of Purified Membranes and Membranous Cell Components for Receptor Studies. Investigations of Membrane-Located Receptors (Methodological Surveys (B): Biochemistry Vol. 12, Eds. Reid, E., Cook, G. M. W. and Morré, D. J., Plenum Publishing Corp., New York, NY (1984) pp. 111-118.
4. Morre, D. J., Creek, K. E., Matyas, G. R., Minnifield, N., Sun, I., Baudoin, P., Morré, D. M. and Crane, F. L.: Free-flow Electrophoresis for Subfractionation of Rat Liver Golgi Apparatus. Biotechniques (1984) 2, 224-233.
5. Morre, D. J., Matyas, G. R. and Mollenhauer, H. H.: Dictyosome-Like Structures from Guinea-Pig Testes Lack Galactosyltransferase, a Golgi Apparatus Marker. Cell Tissue Research (1985) 240, 35-40.
6. Matyas, G. R., Walter-Doelling, V. P., Ferroli, C., Pennington, K. R., Pikaard, D. and Morre, D. J.: Glycolipid Antigens: Potential in Cancer Detection. Investigation and Exploitation of Antibody Combining Sites (Methodological Surveys (B): Biochemistry Vol. 14, Eds. Reid, E., Cook, G. M. W. and Morre, D. J., Plenum Publishing Corp., New York, NY (1986) pp. 323-332.
7. Matyas, G. R., Evers, D. C., Radinsky, R. and Morre, D. J.: Fibronectin Binding to Gangliosides and Rat Liver Plasma Membranes. Experimental Cell Research (1986) 162, 296-318.
8. Sallay, S. I., Promise, W. W., Morre, D. J. and Matyas, G. R.: Ganglioside and PCA Sialic Acid Serum Levels in Cancer. The Cancer Journal (1986) 1, 124-129.
9. Nakane, N., Morgan, D. E., Matyas, G. R., Morre, D. M. and Morré, D. J.: Blood Coagulation Abnormalities in Fischer Strain Rats Bearing Tumors. Life Sciences (1987) 40, 2523-2529.

Gary R. Matyas

Bibliography (cont.)

10. Matyas, G. R., Aaronson, S. A., Brady, R. O. and Fishman, P. H.: Alteration of Glycolipids in ras Transfected NIH 3T3 Cells. Proceedings of the National Academy of Science USA (1987) 84, 6065-6068.
11. Matyas, G. R. and Morre, D. J.: Subcellular Distribution and Biosynthesis of Rat Liver Gangliosides. Biochimica et Biophysica Acta (1987) 921, 599-614.
12. Spiegel, S., Matyas, G. R., Cheng, L. and Sacktor, B.: Asymmetric Distribution of Gangliosides in Renal Brush Border and Basolateral Membranes. Biochimica et Biophysica Acta (1988) 938, 270-278.
13. Matyas, G. R., and Fishman, P. H.: Lipid Signalling Pathways in Normal and Ras-Transfected NIH/3T3 Cells. Cellular Signalling (1989) 1, 395-404.
14. Buckley, N. E., Matyas, G. R. and Spiegel, S.: The Bimodal Growth Response of Swiss 3T3 Cells to the B Subunit of Cholera Toxin Is Independent of the Density of Its Receptor, Ganglioside, GM1. Experimental Cell Research (1990) 189, 13-21.
15. Wassef, N. M., Matyas, G. R. and Alving, C. R.: Complement-Dependent Phagocytosis of Liposomes By Macrophages: Suppressive Effects of 'Stealth Lipids.' Biochemical and Biophysical Research Communications (1991) 176, 866-874.
16. Carl R. Alving, Glenn M. Swartz, Nabila M. Wassef, Edward E. Herderick, Renu Virmani, Frank D. Kolodgie, Gary R. Matyas, Jorge L. Ribas, Julie R. Kenner, and J. Frederick Cornhill. Vaccination Against Cholesterol: Immunologic Modulation of Diet-Induced Hypercholesterolemia and Atherosclerosis. In Atherosclerosis X. Eds. F. P. Woodford, J. Dvignon and A. Sniderman, Excerpta Medica International Congress Series, Elsevier Science, Amsterdam, (1995) pp 944-948.
17. Carl R. Alving, Glenn M. Swartz, Nabila M. Wassef, Edward E. Herderick, Renu Virmani, Frank D. Kolodgie, Gary R. Matyas, Jorge L. Ribas, Julie R. Kenner, and J. Frederick Cornhill. Prospects for an Anti-Cholesterol Vaccine. Clinical Immunotherapy (1995) 3, 409-414.
18. Gregory M. Glenn, Mangala Rao, Roberta L. Richards, Gary R. Matyas, and Carl A. Alving. Murine IgG Subclass Antibodies to Antigens Incorporated in Liposomes Containing Lipid A. Immunological Letters (1995) 47, 73-78.

**Gary R. Matyas**

**Bibliography (cont.)**

19. Carl R. Alving, Glenn M. Swartz, Nabila M. Wassef, Jorge L. Ribas, Edward E. Herderick, Renu Virmani, Frank D. Kolodgie, Gary R. Matyas, and Julie F. Cornhill. Immunization with Cholesterol-Rich Liposomes Induces Anti-Cholesterol Antibodies and Reduces Diet-Induced Hypercholesterolemia and Plaque Formation. Journal Laboratory and Clinical Medicine (1996) 127:40-49.
20. Gary R. Matyas and Carl R. Alving. Protective Prophylactic Immunity Against Intranasal Ricin Challenge Induced by Liposomal Ricin A Subunit. Vaccine Research (1996) 5:163-172.

**MANUSCRIPTS SUBMITTED:**

1. Gregory M. Glenn, Mangala Rao, Gary R. Matyas, Patricia Walker and Carl R. Alving. Transcutaneous Immunization Using Bacterial ADP-Ribosylating Exotoxin. Science (submitted).
2. Mangala Rao, Gary R. Matyas, Franziska Grieder, Kevin Anderson, Peter B. Jahrling, and Carl R. Alving. Cytotoxic T Lymphocytes to Ebola Zaire Virus Are Induced in Mice by Immunization with Liposomes Containing Lipid A. European Journal of Immunology (submitted).

**ABSTRACTS:**

1. Matyas, G. R. and Werderitsh, D. A.: Comparison and Ganglioside Composition of Metastatic and Non-metastatic Transplantable Tumors from the Jaw Region of the Rat. Federation Proceedings (1981) 40, 1544.
2. Morré, D. J., Hsu, H., Matyas, G. R., Kloppel, T., Classen, P. and Jacobson, W.: Lipid-associated Sialic Acid (LASA) Elevated in Sera of Carcinoma Patients. Proceedings of the American Association of Cancer Research (1981) 22, 22.
3. Morgan, D. E., Morré, D. M., and Matyas, G. R.: Effects of Vitamin A on Various Hematological Parameters of Rats Bearing Tumors. Proceedings of the Indiana Academy of Science (1981) 91, 147.
4. Matyas, G. R., Morré, D. J. and Keenan, T. W.: Distribution of Gangliosides Among Subcellular fractions of Rat Liver. Federation Proceedings (1982) 41, 1170.
5. Jacobson, L. B., Putman, J. E., Matyas, G. R., Morré, D. M. and Morré, D. J.: Gamma-glutamyl Transpeptidase Activity of Transformed Rat Hepatocytes. In Vitro (1982) 18, 285.

Gary R. Matyas

Bibliography (cont.)

6. Morré, D. J., Croze, E. M., Matyas, G. R. and Evers, D. C.: Isolated Membrane Fractions for Probing Membrane-Located Receptors in Biochemical Studies. Eighth International Subcellular Methodology Forum (1982) University of Surrey, England.
7. Matyas, G. R. and Morré, D. J.: Cytochemical Localization of Glycosyl Transferases. Journal of Cell Biology (1982) 95, 510.
8. Matyas, G. R., Evers, D. C., Radinsky, R., and Morré, D. J.: Ganglioside Composition of Rodent Tumors and Fibronectin Binding. Proceeding of the American Association of Cancer Research (1983) 24, 27.
9. Matyas, G. R. and Morré, D. J.: Synthesis and Transport of Gangliosides by Rat Liver. Federation Proceedings (1983) 42, 2019.
10. Morré, D. J., Matyas, G. R., Pikaard, D., Chu, A. and Pennington, K.: Levels of Ganglioside-Bound Sialic Acid Elevated in Sera of Cancer Patients. Proceedings of the American Association for Cancer Research (1984) 25, 157.
11. Morré, D. J., Morré, D. M. and Matyas, G. R.: Golgi Apparatus Subfraction by Free-Flow Electrophoresis Separates Cis and Trans Elements. Federation Proceedings (1984) 43, 1715.
12. Matyas, G. R., Pennington, K. and Morré, D. J.: Levels of Ganglioside-Bound Sialic Acid Elevated in Sera of Cancer Patients. Tenth International Subcellular Forum (1984) University of Surrey, England.
13. Matyas, G. R., Creek, K. E., Morré, D. J. and Morré, D. M.: Evidence from Free-Flow Electrophoresis and from Enzyme Cytochemistry from a Cis to Trans Gradient of Galactosyl- and Sialyltransferase Across the Polarity Axis of Rat Liver Golgi Apparatus. Journal of Cell Biology (1984) 99, 104a..
14. Esposito, R. V., Matyas, G. R., Blyden, S. and Morré, D. J.: Molecular Crosslinking to Determine Near Neighbor Relationships Between Fibronectin and Gangliosides of Rat liver plasma Membranes. Federation Proceedings (1986) 45, 1821.
15. Nowack, D., Navas, P., Matyas, G. R., Morré, D. M. and Morré, D. J.: Characteristics of the Golgi Apparatus of Liver-Like Rat Hepatoma RLT-N. Biological Chemistry, Hoppe-Seyler (1986) 367, 152.
16. Matyas, G. R.: Alterantaion of Glycolipids in *ras* Transfected NIH3T3 Cells. Journal of Cellular Biochemistry (1987) Supplement 11D, 152.

## Gary R. Matyas

## Bibliography (cont.)

17. Matyas, G. R.: Elevations of Diacylglycerol in *ras* Transfected NIH/3T3 Cells Are Not From Phosphoinositide Hydrolysis. Journal of Cell Biology (1988) 107, 705a.
18. Buckley, N., Matyas, G. R. and Spiegel, S.: Bimodal Regulation of Cell Growth By Gangliosides. Proceedings of the Xth International Symposium on Glycoconjugates (1989) 290.
19. Matyas, G. R., Wasef, N. M., Wilhelmsen, C. I., Johnson, A. J. and Alving, C. R.: Concanavalin A: Cytotoxic Effects on Murine Macrophage P388D Cells and Physiologic Effects of Toxic Doses *in Vivo*. The FASEB Journal (1990) 4, 1989.
20. Wasef, N. M., Matyas, G. R. and Alving, C. R.: Complement-Dependent Phagocytosis of Liposomes by Macrophages: Suppressive Effects of Gangliosides and Phosphatidylinositol. The FASEB Journal (1990) 4, 2141.
21. Buckley, N. E., Matyas, G. R. and Spiegel, S.: Swiss 3T3 Fibroblasts Display a Bimodal Growth Response to the B Subunit of Cholera Toxin Independent of the Concentration of Ganglioside GM1. The FASEB Journal (1990) 4, 1912.
22. Mayorga, M. A., Matyas, G. R., Wilhelmsen, C. L., Banks, R. E. and Alving, C. R.: Acute Respiratory Injury Induced By Endotracheally Instilled Snake Venom Phospholipase A<sub>2</sub> (PLA<sub>2</sub>). The FASEB Journal (1991) 5, 1268.
23. Matyas, G. R. and Fishman, P. H.: Endogenous Gangliosides Do Not Modulate But Are Modulated By Cell Growth in Murine 3T3 Cells. The FASEB Journal (1991) 5, 1547.
24. Mayorga, M.A., Matyas, G., Wilhelmsen, C., Banks, R., Alving C.: Production of Monoclonal Antibodies to Phospholipase A<sub>2</sub>: Potential Antidote for Phospholipase A<sub>2</sub> Toxicity. American College of Physicians, Army Regional Meeting, San Francisco, CA 4-8 Nov 92.
25. Matyas, G. R. and Alving, C. R.: Effect of Route of Administration on Generation of Different Isotype Antibodies to Liposome-Encapsulated Ricin Subunits. The FASEB Journal (1994) 8, A681.
26. Matyas, G. R. and Alving, C. R.: Effect of Route of Administration on Generation of Different Isotype Antibodies to Liposome-Encapsulated Ricin Subunits. The FASEB Journal (1994) 8, A1464.
27. G. M. Glenn, M. Rao, R. Owens, G. Matyas, C. R. Alving. Murine IgG Subclass and T-helper Response to Cholera Toxin and Spf56 Incorporated in Liposomes Containing Lipid A. Presented National Meeting of Leukocyte Biology, 20-24 September 94.

**Gary R. Matyas****Bibliography (cont.)**

28. Alving, C. R., Swartz, G. M., Wassef, N. M., Herderick, E. E., Virmani, R., Kolodgie, F. D., Matyas, G. R., Ribas, J. L., Kenner, J. R., and Cornhill, J. F. . Vaccination Against Cholesterol: Immunologic Modulation of Diet-Induced Hypercholesterolemia and Atherosclerosis. X<sup>TH</sup> International Symposium on Atherosclerosis, Montreal, 09-14 October 1994.
29. Matyas, G. R. and Alving, C. R.: Production of Serum IgA and High Titer IgG Antibodies by Intranasal Immunization with Liposome-Encapsulated Ricin Subunits. The FASEB Journal (1995) 9, A216.
30. Matyas, G. R. and Alving, C. R.: Protection Against Ricin by Intranasal Immunization with Liposomes. FASEB Journal (1996)10:A1190.
31. Harris, D. T., Mastrangelo, M. J., Alving, C., Matyas, G., Hwang, M., Cox, J., Maida, A. and Spitler, L. E.: Active Specific Immunization of Patients with Hormone-Refractory Prostate Cancer Using OncoVax-P<sup>TM</sup>. Proceedings of the American Society of Clinical Oncology (1996) 15, 555.
32. Talmadge, J., Muderhwa, J., Alving, C., Matyas, G., Hwang, M., Maida, A., Spitler, L.: Preclinical Evaluation of OncoVax-P<sup>TM</sup>, a Prostate Cancer Vaccine. Proceedings of the American Association for Cancer Research (1996), 37, 477.
33. Talmadge, J., Muderhwa, J., Alving, C., Matyas, G., Hwang, M., Maida, A. and Spitler, L.: GM-CSF as an Adjuvant with OncoVax-P<sup>TM</sup>, a Prostrate Cancer Vaccine. Proceedings of the American Association for Cancer Research (1997) 38, 400.

# INDUCTION OF CYTOTOXIC T-LYMPHOCYTES TO TUMOR CELLS PRESENTING PROSTATE SPECIFIC ANTIGENS




Exhibit B

Matyas

## Induction of Antitumor Response in Mice by Prostate Cancer Vaccine

Gary Maryas, PhD, Mangala Rao, PhD, Jean Muderhwa, PhD, and Carl Alving, MD, Walter Reed Army Institute of Research, Washington, DC

We report that immunization of mice with OncoVax-P<sup>TM</sup> prostate cancer vaccine induces cytotoxic T-lymphocytes which have the capability of killing tumor cells presenting PSA antigens.

Two groups of Balb/c mice (6 mice/group) were immunized with OncoVax-P<sup>TM</sup>. One group was immunized with OncoVax-P<sup>TM</sup> alone and the other group received OncoVax-P<sup>TM</sup> mixed with aluminum hydroxide (alum, Alhydrogel) (200 µg Al<sup>+++</sup>). OncoVax-P<sup>TM</sup> is a liposomal formulation of prostate specific antigen (PSA) with lipid A, as an adjuvant. The PSA dose was 5 µg PSA and 20 µg of lipid A. The mice were immunized at week 0 and 4 weeks after the boost. Three animals per group were euthanized 4 weeks after the boost and the spleens were removed for CTL assay. The cells from each group of spleens were pooled and incubated 5 days with media alone or 2 µg/ml human PSA. Target P815 cells (mouse mastocytoma) were infected with either wild type vaccinia virus (WTvac) or with vaccinia virus transfected with PSA gene and the *E. coli* lac Z gene (PSA<sub>vac</sub>, Therion Biologics Corporation) at an multiplicity of infection of 10. P815 cells were incubated with 10 µg/ml of peptide, CYASGWGSI, which represents a potential murine CTL epitope for PSA. It was identified using the University of Wisconsin Genetics Computer Group sequence analysis finding patterns computer program. This program was used to compare the amino acid sequence of PSA with the known murine CTL anchor sequences. CYASGWGSI is located at amino acid positions 128-137 of PSA. The P815 targets were incubated for 16 hours with vaccinia viruses or peptide. The targets cells were then labeled with Cr<sup>51</sup> (0.1 µCi/10<sup>6</sup> cells) for one hour. Effector cells were harvested and plated in 96 well U bottom plates. Cr<sup>51</sup> labeled targets were added at various effector:target ratios. Following centrifugation at approximately 50 X g for 5 min, the plates were incubated at 37°C for 5 hr. The radioactivity present in the supernatant was harvested using Skatron wicks and the radioactivity was quantified using a gamma counter.



As shown in the attached figure, murine CTL which specifically lysed PSAvac infected targets (A & B) and targets incubated with peptide (E) were obtained. Approximately, 47% cell lysis was obtained using PSAvac targets. WTvac targets were not lysed (C & D), indicating the CTLs were specific for PSA epitopes. Addition of alum to the vaccine had no effect on the generation of CTL which lysed PSAvac targets (A & B) but it inhibited the induction of CTLs to tumor cells pulsed with peptide.

These results indicate that immunization of mice with the prostate cancer vaccine induces lymphocytes capable of specifically killing tumor cells presenting PSA antigens indicating an antitumor response.